High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT

Inclusion Criteria: * Male and female patients of any ethnic group aged between 18 and 65 years * HIV-positive patients with malignant diseases of the blood (NHL, Hodgkin disease, plasmocytoma, acute and chronic leukaemia) who failed to achieve complete remission (CR) after standard-dose first-line chemotherapy or had a chemosensitive relapse after an initial CR * Patients must receive HAART Exclusion Criteria: * Any of the following conditions: * congestive heart failure (NYHA \> II) * documented EBV, HBV or HCV infection (only for allogeneic PBSCT) * creatinine clearance \< 60 ml/min * left ventricular ejection fraction \< 40% * bilirubin \> 2 mg/dl * Severe opportunistic infection * More than 10% of bone marrow involved with lymphoma * Between 2 and 5 10\^6 autologous CD34+ cells/kg BW obtained after leukapheresis and CD34 enrichment * Women of child.bearing potential not under adequate contraceptive protection * Women who are pregnant or breast feeding * Known history of drug-, medication- or alcohol abuse within the last 12 months preceding the study * Participation in another study with an investigational product within less than one month prior to this study * Simultaneous participation in a study with an investigational drug * Presence of any disease likely to require procedures altering the schedule of the protocol * Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in th…